Robert S. Landsman

Array ( [id] => 19825310 [patent_doc_number] => 12246064 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-11 [patent_title] => Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate [patent_app_type] => utility [patent_app_number] => 17/152585 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10130 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17152585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20480390 [patent_doc_number] => 12528861 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-20 [patent_title] => Anti-human-IL-1-bantibodies, encoding nucleic acids thereof and methods of using thereof to treat inflammatory diseases and cancer [patent_app_type] => utility [patent_app_number] => 17/759059 [patent_app_country] => US [patent_app_date] => 2021-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4888 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16822582 [patent_doc_number] => 20210137875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM [patent_app_type] => utility [patent_app_number] => 17/149229 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17149229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16962949 [patent_doc_number] => 20210214448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => CCR5 BINDING AGENT FOR THE TREATMENT OF CCR5 POSITIVE METASTATIC CANCER [patent_app_type] => utility [patent_app_number] => 17/148281 [patent_app_country] => US [patent_app_date] => 2021-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14456 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17148281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18995931 [patent_doc_number] => 11912758 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-27 [patent_title] => Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel [patent_app_type] => utility [patent_app_number] => 17/146187 [patent_app_country] => US [patent_app_date] => 2021-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 36 [patent_no_of_words] => 14970 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17146187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036767 [patent_doc_number] => 20210253725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => AGONISTIC TNF RECEPTOR BINDING AGENTS [patent_app_type] => utility [patent_app_number] => 17/144591 [patent_app_country] => US [patent_app_date] => 2021-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 171278 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17144591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977660 [patent_doc_number] => 20210221897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => METHODS OF TREATING CANCER WITH NONFUCOSYLATED ANTI-CD70 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/134963 [patent_app_country] => US [patent_app_date] => 2020-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38755 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17134963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17243479 [patent_doc_number] => 20210363222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => Soluble TNF Receptors and Their Use in Treatment of Disease [patent_app_type] => utility [patent_app_number] => 17/135980 [patent_app_country] => US [patent_app_date] => 2020-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17135980 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977669 [patent_doc_number] => 20210221906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => CARBONIC ANHYDRASE IX SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/129369 [patent_app_country] => US [patent_app_date] => 2020-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17129369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18910364 [patent_doc_number] => 11873334 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF [patent_app_type] => utility [patent_app_number] => 17/117993 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 36 [patent_no_of_words] => 60966 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17117993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16993225 [patent_doc_number] => 20210231645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => METHODS AND COMPOSITIONS FOR INVESTIGATING MULTIPLE DRUG-DRUG TRANSPORTER INTERACTIONS [patent_app_type] => utility [patent_app_number] => 17/118267 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16749979 [patent_doc_number] => 20210101988 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES [patent_app_type] => utility [patent_app_number] => 17/118441 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 102661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16900808 [patent_doc_number] => 20210179724 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => VARIANT NUCLEIC ACID LIBRARIES FOR ADENOSINE RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/116939 [patent_app_country] => US [patent_app_date] => 2020-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39916 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17116939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807928 [patent_doc_number] => 20210130481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => ANTIBODIES AGAINST THE HUMAN FSHR EXTRACELLULAR DOMAIN [patent_app_type] => utility [patent_app_number] => 17/116115 [patent_app_country] => US [patent_app_date] => 2020-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17116115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18182305 [patent_doc_number] => 20230043034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => ANTI-C5 ANTIBODY FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER [patent_app_type] => utility [patent_app_number] => 17/783106 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29921 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16976233 [patent_doc_number] => 20210220470 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => METHODS FOR TREATING DIGITALLY-IDENTIFIED IL-4/IL-13 RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 17/115618 [patent_app_country] => US [patent_app_date] => 2020-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58074 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17115618 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18093194 [patent_doc_number] => 20220411535 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => COMPOSITIONS AND METHODS FOR UPREGULATING HLA CLASS I ON TUMOR CELLS [patent_app_type] => utility [patent_app_number] => 17/778317 [patent_app_country] => US [patent_app_date] => 2020-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17778317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16961616 [patent_doc_number] => 20210213115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-15 [patent_title] => PEPTIDE VACCINE THERAPY FOR TREATMENT OF FRa-EXPRESSING TUMORS [patent_app_type] => utility [patent_app_number] => 17/101985 [patent_app_country] => US [patent_app_date] => 2020-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17101985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18346461 [patent_doc_number] => 20230134571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => ENGINEERED ANTIBODIES TO HIV ENV [patent_app_type] => utility [patent_app_number] => 17/772561 [patent_app_country] => US [patent_app_date] => 2020-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16613671 [patent_doc_number] => 20210032324 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => ANTIBODY MOLECULES TO A PROLIFERATION-INDUCING LIGAND (APRIL) [patent_app_type] => utility [patent_app_number] => 17/074857 [patent_app_country] => US [patent_app_date] => 2020-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 135535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17074857 [rel_patent_id] =>[rel_patent_doc_number] =>)